Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China.
Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi 563006, Guizhou Province, China.
World J Gastroenterol. 2024 Oct 28;30(40):4393-4398. doi: 10.3748/wjg.v30.i40.4393.
Liver diseases pose a significant threat to human health. Although effective therapeutic agents exist for some liver diseases, there remains a critical need for advancements in research to address the gaps in treatment options and improve patient outcomes. This article reviews the assessment of Elafibranor's effects on liver fibrosis and intestinal barrier function in a mouse model of alcoholic liver disease (ALD), as reported by Koizumi in the . We summarize the impact and mechanisms of Elafibranor on ALD, metabolic-associated fatty liver disease, and cholestatic liver disease based on current research. We also explore its potential as a dual agonist of PPARα/δ, which is undergoing Phase III clinical trials for metabolic-associated steatohepatitis. Our goal is to stimulate further investigation into Elafibranor's use for preventing and treating these liver diseases and to provide insights for its clinical application.
肝脏疾病对人类健康构成重大威胁。尽管某些肝脏疾病已有有效治疗药物，但仍迫切需要在研究方面取得进展，以填补治疗选择的空白并改善患者的预后。本文综述了 Koizumi 在《.》杂志上发表的关于 Elafibranor 对酒精性肝病（ALD）小鼠模型肝纤维化和肠道屏障功能影响的研究。我们根据现有研究总结了 Elafibranor 对 ALD、代谢相关脂肪性肝病和胆汁淤积性肝病的作用及其机制。我们还探讨了它作为 PPARα/δ 双重激动剂的潜力，目前正在进行代谢相关脂肪性肝炎的 III 期临床试验。我们的目标是鼓励进一步研究 Elafibranor 在预防和治疗这些肝脏疾病中的应用，并为其临床应用提供思路。
